Therefore, understanding the mechanism underlying programmed death‐ligand 1 (PD‐L1) expression and identification of markers enabling better prediction of the benefit from targeting the PD‐L1/PD‐1 axis could provide innovative treatment regimens for CRC patients. This evidence concerns the gene PDCD1 and colorectal carcinoma.